Payment overview · 2025
General Payments
$1,028.03
57 reported records · 10 companies
Healthcare provider profile · identity verified
Will D Heise, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHOCTAW, OK · NPI 1962840504
Verified facts
What the public records show
CMS Open Payments records show Will D Heise, MD received $1,028.03 in general payments during 2025 across 57 reported records.
ABBVIE INC. accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $285.00 | 27.7% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $194.92 | 19.0% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $170.52 | 16.6% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.49 | 14.8% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $56.47 | 5.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.81 | 5.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.01 | 4.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.19 | 3.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.33 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.29 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,028.03 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $166.22 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $136.97 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $121.61 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.27 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $113.27 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $95.96 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $91.03 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $87.79 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $84.15 | 4 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $82.12 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.56 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.56 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $56.47 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.01 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
128 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 594 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 529 | 144 |
| Losartan Potassium | Losartan Potassium | 377 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 100 |
| Allopurinol | Allopurinol | 300 | 85 |
| Citalopram Hbr | Citalopram Hydrobromide | 279 | 84 |
| Lisinopril | Lisinopril | 269 | 68 |
| Omeprazole | Omeprazole | 266 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 74 |
| Gabapentin | Gabapentin | 251 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 63 |
| Trazodone Hcl | Trazodone Hcl | 209 | 65 |
| Alprazolam | Alprazolam | 207 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 198 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 82 |
| Potassium Chloride | Potassium Chloride | 193 | 53 |
| Metformin Hcl | Metformin Hcl | 192 | 58 |
| Methylprednisolone | Methylprednisolone | 179 | 139 |
| Furosemide | Furosemide | 178 | 55 |
| Tramadol Hcl | Tramadol Hcl | 177 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 47 |
| Simvastatin | Simvastatin | 158 | 47 |
| Famotidine | Famotidine | 148 | 53 |
| Celecoxib | Celecoxib | 146 | 47 |
| Montelukast Sodium | Montelukast Sodium | 138 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 135 | 54 |
| Metformin Hcl Er | Metformin Hcl | 128 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 128 | 37 |
| Pregabalin | Pregabalin | 126 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 37 |
| Amitriptyline Hcl | Amitriptyline Hcl | 105 | 29 |
| Eliquis | Apixaban | 104 | 26 |
| Meloxicam | Meloxicam | 103 | 36 |
| Glimepiride | Glimepiride | 102 | 26 |
| Ipratropium Bromide | Ipratropium Bromide | 101 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 100 | 30 |
| Aripiprazole | Aripiprazole | 97 | 31 |
| Finasteride | Finasteride | 95 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 30 |
| Glipizide | Glipizide | 88 | 27 |
| Alendronate Sodium | Alendronate Sodium | 87 | 32 |
| Doxepin Hcl | Doxepin Hcl | 87 | 25 |
| Ozempic | Semaglutide | 82 | 19 |
| Ondansetron Odt | Ondansetron | 81 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 25 |
| Cephalexin | Cephalexin | 79 | 58 |
| Carvedilol | Carvedilol | 70 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 22 |
| Jardiance | Empagliflozin | 68 | 20 |
| Azelastine Hcl | Azelastine Hcl | 66 | 40 |
| Lactulose | Lactulose | 65 | 26 |
| Synthroid | Levothyroxine Sodium | 65 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 24 |
| Azithromycin | Azithromycin | 59 | 53 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 16 |
| Buspirone Hcl | Buspirone Hcl | 57 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 42 |
| Sertraline Hcl | Sertraline Hcl | 54 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 18 |
| Methocarbamol | Methocarbamol | 53 | 27 |
| Atenolol | Atenolol | 51 | 15 |
| Estradiol | Estradiol | 51 | 18 |
| Baclofen | Baclofen | 49 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 47 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 46 | 20 |
| Glipizide Er | Glipizide | 45 | 13 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Prednisone | Prednisone | 45 | 24 |
| Trulicity | Dulaglutide | 45 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 19 |
| Spironolactone | Spironolactone | 42 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 12 |
| Valacyclovir | Valacyclovir Hcl | 38 | 22 |
| Constulose | Lactulose | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Acyclovir | Acyclovir | 35 | 17 |
| Acarbose | Acarbose | 33 | 13 |
| Fluconazole | Fluconazole | 32 | 23 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 24 |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Nystatin | Nystatin | 31 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 31 | 21 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Topiramate | Topiramate | 26 | 12 |
| Cefdinir | Cefdinir | 25 | 21 |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Cilostazol | Cilostazol | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 13 |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Probenecid | Probenecid | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,028.03 · 57 records | ABBVIE INC. | AIRSUPRA, AREXVY, Cologuard Collection Kit, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Saxenda, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error